Epilepsy currently affects more than 400,000 people in the United Kingdom and 2.3 million in the United States. Drug therapy is the mainstay of treatment for patients with epilepsy, but therapies vary widely in their mechanism of action and acquisition cost. This article describes a decision model developed for the National Institute for Clinical Excellence in the United Kingdom. It compares the long-term cost-effectiveness of drugs licensed in adults for use in 3 situations: monotherapy for newly diagnosed patients, monotherapy for refractory patients, and combination therapy for refractory patients. The analysis separately considers the treatment of partial and generalized seizures. The full range of pharmaceutical therapies feasibly used in the UK health system was included in the analysis. The analysis showed that, on the basis of existing evidence, for newly diagnosed patients with partial seizures, carbamazepine and valproate are likely to be the most cost-effective mono-therapies. Carbamazepine is likely to be the most cost-effective 2nd-line monotherapy for refractory patients, and oxcarbazepine would probably be the most cost-effective adjunctive therapy for refractory patients if the willingness to pay for additional health benefits is greater than £18,000 per quality-adjusted life year (QALY). For patients with generalized seizures, valproate is most likely to be cost-effective for newly diagnosed patients. For refractory patients, adjunctive topiramate is more cost-effective than monotherapy alone if the willingness to pay for additional health benefits is greater than £35,000 per QALY. There is, however, considerable uncertainty regarding these results. Some of the methodological features of the study will be of value in designing cost-effectiveness analyses of other therapies for chronic conditions. These include the methods used to deal with the absence of head-to-head trial data and the need to reflect time dependency in Markov transition probabilities.
National Statistics Office. Epilepsy prevalence and prescribing patterns in England and Wales. Health Stat Quart. 2002;15:23–30.
2.
Office for National Statistics. Mortality Statistics: General. Review of the Registrar General on Deaths in England and Wales, 2000. London: Office for National Statistics; 2000.
3.
Kobau R. Health related quality of life among persons with epilepsy. Morb Mortal Wkly Rep. 2001;50:24–26.
4.
National Institute for Clinical Excellence. Full Guidance for Newer Drugs for Epilepsy in Adults. London: National Institute for Clinical Excellence; 2004.
5.
Wilby J, Kainth A, Hawkins N, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess. In press.
6.
National Institute for Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. London: NICE; 2004.
7.
Commission on Classification and Terminology of the International League against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981;22:489–501.
8.
British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2002.
9.
Department of Health. Policy Appraisal and Health. London: Department of Health; 1995.
10.
Billingham LJ, Abrams KR, Jones DR. Methods for the analysis of quality-of-life and survival data in health technology assessment. Health Technol Assess. 1999;3(10).
11.
Lhatoo SD, Sander JWAS, Shorvon SD. The dynamics of drug treatment in epilepsy: an observational study in an unselected population based cohort with newly diagnosed epilepsy followed up prospectively over 11-14 years. J Neurol Neurosurg Psychiatry. 2001;71:632–637.
12.
Venables WN, Smith DM, R Development Core Team. An introduction to R: a programming environment for data analysis and graphics. Available from: http://cran.r-project.org/doc/manuals/Rintro.pdf
13.
Hawkins N, Sculpher M, Epstein D. Cost-effectiveness analysis of treatments for chronic disease: using R to incorporate time-dependency of treatment response. Med Decis Making. In press.
14.
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–319.
15.
Ades A. A chain of evidence with mixed comparisons: models for multi-parameter evidence synthesis and consistency of evidence. Stat Med. 2003;22:2995–3016.
16.
Ades A, Cliffe S. Markov chain Monte Carlo estimation of a multi-parameter decision model: consistency of evidence and the accurate assessment of uncertainty. Med Decis Making. 2002;22: 359–371.
17.
Gilks WR, Thomas A, Spiegelhalter DJ. A language and program for complex Bayesian modelling. Statistician. 1994;1994(43):169–178.
18.
Gilks WR, Richardson S, Spiegelhalter DJ. Markov Chain Monte Carlo in Practice. London: Chapman & Hall/CRC; 1996.
19.
Abbott Laboratories. An Open-Label Extension Study of Tiagabine HCl in the Treatment of Patients with Partial Seizures. Abbott Park, IL: Abbott Laboratories; 1998.
20.
Lhatoo SD, Johnson AL, Goodridge DM, MacDonald BK, Sander JWAS, Shorvon SD. Mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort. Ann Neurol. 2001;49:336–344.
21.
Drummond M, O’Brien B, Stoddard G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. Oxford, UK: Oxford University Press; 1997.
22.
Selai CE, Trimble M, Price ML. Evaluation of the relationship between epilepsy severity and utility. In: ISPOR Fifth Annual European Conference; 3–5 November 2002; Rotterdam, the Netherlands.
23.
Heaney DC, Shorvon SD, Sander JW. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia. 1998;39(suppl 3):S19–S25.
24.
Jacoby AB, Baker D, McNamee G, Graham-Jones P, Chadwick D. Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia. 1998;39:776–786.
25.
Netten A, Curtis L. Unit Costs of Health and Social Care. Canterbury, UK: PSSRU, University of Kent; 2002.
26.
Department of Health. NHS Executive. The New NHS: 2002 Reference Costs. Leeds, UK: Department of Health; 2002.
27.
Briggs A, Goeree R, Blackhouse G, O’Brien B. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophagael reflux disease. Med Decis Making. 2002;22:290–308.
28.
Johannesson M, Weinstein S. On the decision rules of cost-effectiveness analysis. J Health Econ. 1993;12:459–467.
29.
Van Hout BA AM, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994;3:309–319.
30.
Briggs AH. Handling uncertainty in cost effectiveness models. Pharmacoeconomics. 2000;17:479–500.
31.
Kerr M. An Open Randomised Comparison of Add-On Lamotrigine or Valproate/Carbamazepine Withdrawing to Monotherapy in Patients with Treatment Resistant Epilepsy. Report No. SCAB3001 (105-133). Critchley Park, UK: Glaxo Wellcome UK Ltd.; 2001.
32.
GlaxoSmithKline. An Open Randomised Comparison of Lamotrigine with Valporate as Monotherapy in Patients with Idiopathic Generalised Epilepsy. Critchley Park, UK: Glaxo Wellcome UK Ltd.; 2001.
33.
Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ. 1996;5:513–524.
34.
Claxton KSM, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence. Lancet. 2002;360:711–715.
35.
Bryant J, Stein K. Lamotrigine as Monotherapy for Epilepsy in Adults. Southampton, UK: Wessex Institute for Health Research and Development; 1998.
36.
Heaney DC, Shorvon SD, Sander JW, et al. Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries. Epilepsia. 2000;41(suppl 5):S37–S44.
37.
Shakespeare A, Simeon G. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK. Seizure. 1998;7:119–125.
38.
Remak E, Price M. A Markov model of treatment of newly diagnosed epilepsy in the UK: An initial assessment of cost-effectiveness of topiramate. Eur J Health Econ. 2003;4:271–278.
39.
Selai CE, Smith K, Trimble MR. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs. Seizure. 1999;8:8–13.
40.
Hughes D, Cockerell OC. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy. Seizure. 1996;5:89–95.
41.
Schachter SC, Sommerville KW, Ryan JE. A cost-effectiveness analysis of tiagabine, phenytoin, and carbamazepine adjunctive therapy for patients with complex partial seizures. Neurology. 1999;52(suppl 6):A143-A143.
42.
O’Neill BA, Trimble MR, Bloom DS. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options. Seizure. 1995;4:37–44.
43.
Markowitz MA, Mauskopf JA, Halpern MT. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy. Neurology. 1998;51:1026–1033.
44.
Messori A, Trippoli S, Becagli P, Cincotta M, Labbate MG, Zaccara G. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol. 1998;53:421–427.
45.
Reinharz DK, Contandriopoulos W, Tessier AP, Champagne G. The economic effects of introducing vigabatrin, a new antiepileptic medication. Pharmacoeconomics. 1995;8:400–409.
46.
Adab N, Winterbottom J, Tudur Smith C, Williamson PR. Common Antiepileptic Drugs in Pregnancy in Women with Epilepsy (Protocol for a Cochrane Review). Oxford, UK: Cochrane Library, Update Software; 2002.
47.
Song F, Altman D, Glenny A-M, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J. 2003;326:326–475.
48.
Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet. 1995;345:476–479.
49.
Nieto Barrera M, Brozmanova M, Capovilla G, et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res. 2001;46:145–155.
50.
Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001;56:172–177.
51.
Reunanen M, Dam M, Yuen AW. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res. 1996;23:149–155.
52.
Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia. 1999;40:601–607.
53.
Aikia M, Kalviainen R, Sivenius J, Halonen T, Riekkinen PJ. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res. 1992;11:199–203.
54.
Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 1997;27:195–204.
55.
Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 1997;26:451–460.
56.
Privitera M, Brodie M, Mattson R, Chadwick D, Neto W, Wang S. Topiramate, Carbamazepine and Valproate Monotherapy: Double-Blind Comparison in Newly Diagnosed Epilepsy. High Wycombe, UK: Janssen-Cilag Ltd.; 2002.
57.
UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet. 1990;335:1114–1117.
58.
US Gabapentin Study Group No 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology. 1993;43:2292–2298.
59.
Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia. 2000;41:1179–1186.
60.
Cereghino JJ, Biton V, Abou Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55:236–242.
61.
Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure. 2000;9:80–87.
62.
Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology. 1993;43:2284–2291.
63.
Veendrick-Meekes MJBM, Beun AM, Carpay JA, Arends LR, Schlosser A. Use of Lamictal® as adjunctive therapy in patients with mental retardation and epilepsy: final analysis of a double-blind study with evaluation of behavioural effects. Poster presentation at: 4th European Congress of Epileptology, 7–12 Oct 2000; Florence, Italy.
64.
Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 2000;41:1597–1607.
65.
Sachdeo RC, Leroy RF, Krauss GL, et al. Tiagabine therapy for complex partial seizures: a dose-frequency study. Arch Neurol. 1997;54:595–601.
66.
Uthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol. 1998;55:56–62.
67.
Kalviainen R, Brodie MJ, Duncan J, Chadwick D, Edwards D, Lyby K. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Epilepsy Res. 1998;30:31–40.
68.
Guberman A, Neto W, Gassman-Mayer C. Low dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand. 2002;106:183–189.
69.
Yen DJ, Yu HY, Guo YC, Chen C, Yiu CH, Su MS. A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia. 2000;41:1162–1166.
70.
Sharief M, Viteri C, Ben Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res. 1996;25:217–224.
71.
Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology. 1996;46:1684–1690.
72.
Barrett J, Gassman C, Lim P, Hughson C, Zimmerman T. Topiramate (RWJ-17021-000) Clinical Trial in Primary Generalised Tonic-Clonic Seizures. Report No. YTC-E. New Jersey: R. W. Johnson; 1997.
73.
Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology. 1999;52:1330–1337.
